# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-24-000038
Filing Date
2024-05-09
Accepted
2024-05-09 16:37:10
Documents
7
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | q12024form6-k.htm | 6-K | 22445
2 | EX-99.1 2024 FIRST QUARTER INTERIM FINANCIAL STATEMENTS | ex991-interimfsmarch312024.htm | EX-99.1 | 338502
3 | EX-99.2 2024 FIRST QUARTER MD&A | ex992-q12024mda.htm | EX-99.2 | 194051
4 | EX-99.3 Q1 2024 CERTIFICATION CEO | ex993-q12024certificationx.htm | EX-99.3 | 14384
5 | EX-99.4 Q1 2024 CERTIFICATION CFO | ex994-q12024certificationx.htm | EX-99.4 | 14281
6 |  | oncolyticslogotaglinebluea.jpg | GRAPHIC | 355294
7 |  | pipeline002.jpg | GRAPHIC | 639632
| Complete submission text file | 0001129928-24-000038.txt |  | 1904684

Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 24931393
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)